Skip to main content
Manali Kamdar, MD, Oncology, Denver, CO

ManaliKamdarMD

Oncology Denver, CO

Hematologic Oncology

Physician

Dr. Kamdar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kamdar's full profile

Already have an account?

  • Office

    2190 E 11th Avenue
    2190 E 11th Avenue
    Denver, CO 80206
    Phone+1 252-847-4268

Education & Training

  • Vidant Medical Center/East Carolina University
    Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
  • ECU Health Medical Center/East Carolina University
    ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2007 - 2010
  • KJ Somaiya Medical College
    KJ Somaiya Medical CollegeClass of 2004

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2013 - Present
  • CO State Medical License
    CO State Medical License 2014 - 2025
  • WY State Medical License
    WY State Medical License 2021 - 2025
  • NC State Medical License
    NC State Medical License 2007 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
    Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
    Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Sin... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • School of Medicine Honors Distinguished Clinicians
    School of Medicine Honors Distinguished CliniciansMarch 29th, 2023
  • Why Is CAR T-cell Therapy ‘One of the Most Phenomenal Advances in Science’?
    Why Is CAR T-cell Therapy ‘One of the Most Phenomenal Advances in Science’?August 16th, 2022
  • CAR T-cell Therapy Transforming Science and Cancer Patient Outcomes at CU Anschutz
    CAR T-cell Therapy Transforming Science and Cancer Patient Outcomes at CU AnschutzAugust 15th, 2022
  • Join now to see all